Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Clinical trial NCT06922591 · RECRUITING

Trial details

NCT number: NCT06922591
Sponsor: Tango Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

PDAC PDAC - Pancreatic Ductal Adenocarcinoma NSCLC RAS Mutation MTAP Deletion Lung Cancer Pancreatic Cancer Metastatic Thoracic Cancer

Start date: 2025-05-31
Primary completion: 2027-06-01
Enrollment: 183

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.